Home›Trial›NCT01651403
🔬NCT01651403Phase 3ACTIVE NOT RECRUITING

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection

Study Summary

The primary objective of this study is to evaluate the antiviral efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) versus placebo in pediatric population (aged 2 to \< 12 years at the time of enrollment) with chronic hepatitis B (CHB) infection.

Conditions
Chronic Hepatitis B
Interventions / Drugs
Tenofovir DFTDF Placebo
View on ClinicalTrials.gov ↗
Sponsor
GILD
Gilead Sciences
Antiviral
F24/100
Study Details
Enrollment90 participants
Primary Completion—
Lead SponsorGilead Sciences
Data Retrieved2026-04-11 02:55:27.112403+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.